thiophenes has been researched along with erdafitinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Obaidy, KI; Cheng, L | 1 |
| Hubert, P; Loriot, Y; Selmani, Z; Thiery-Vuillemin, A | 1 |
1 review(s) available for thiophenes and erdafitinib
| Article | Year |
|---|---|
Fibroblast growth factor receptor (
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma; Exons; Gene Amplification; Gene Fusion; Genetic Predisposition to Disease; Humans; Molecular Targeted Therapy; Mutation, Missense; Phenotype; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 3; Thiophenes; Urinary Bladder Neoplasms; Urothelium | 2021 |
1 other study(ies) available for thiophenes and erdafitinib
| Article | Year |
|---|---|
FGFR alterations in urothelial carcinoma: Picking the right target.
Topics: Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Gene Fusion; Humans; Molecular Targeted Therapy; Morpholines; Mutation; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Thiophenes; Urinary Bladder Neoplasms | 2021 |